A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells - PubMed (original) (raw)
. 2014 Mar 1;88(1):36-45.
doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.
Yongchuan Gu 2, Donya Moradi Manesh 3, Jad El-Hoss 3, Duohui Jing 3, Karen L Mackenzie 3, Christopher P Guise 1, Annika Foehrenbacher 2, Susan M Pullen 2, Juliana Benito 4, Jeffrey B Smaill 1, Adam V Patterson 1, Medhanie A Mulaw 5, Marina Konopleva 4, Stefan K Bohlander 6, Richard B Lock 3, William R Wilson 7
Affiliations
- PMID: 24434189
- DOI: 10.1016/j.bcp.2013.12.019
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells
Stephen M F Jamieson et al. Biochem Pharmacol. 2014.
Abstract
Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) metabolises steroid hormones, prostaglandins and xenobiotics, and activates the dinitrobenzamide mustard prodrug PR-104A by reducing it to hydroxylamine PR-104H. Here, we describe a functional assay for AKR1C3 in cells using the fluorogenic probe coumberone (a substrate for all AKR1C isoforms) in conjunction with a specific inhibitor of AKR1C3, the morpholylurea SN34037. We use this assay to evaluate AKR1C3 activity and PR-104A sensitivity in human leukaemia cells. SN34037-sensitive reduction of coumberone to fluorescent coumberol correlated with AKR1C3 protein expression by immunoblotting in a panel of seven diverse human leukaemia cell lines, and with SN34037-sensitive reduction of PR-104A to PR-104H. SN34037 inhibited aerobic cytotoxicity of PR-104A in high-AKR1C3 TF1 erythroleukaemia cells, but not in low-AKR1C3 Nalm6 pre-B cell acute lymphocytic leukaemia (B-ALL) cells, although variation in PR-104H sensitivity confounded the relationship between AKR1C3 activity and PR-104A sensitivity across the cell line panel. AKR1C3 mRNA expression showed wide variation between leukaemia patients, with consistently higher levels in T-ALL than B-ALL. In short term cultures from patient-derived paediatric ALL xenografts, PR-104A was more potent in T-ALL than B-ALL lines, and PR-104A cytotoxicity was significantly inhibited by SN34037 in T-ALL but not B-ALL. Overall, the results demonstrate that SN34037-sensitive coumberone reduction provides a rapid and specific assay for AKR1C3 activity in cells, with potential utility for identifying PR-104A-responsive leukaemias. However, variations in PR-104H sensitivity indicate the need for additional biomarkers for patient stratification.
Keywords: Aldo-keto reductase 1C3; Fluorogenic assays; Leukaemia; PR-104; SN34037.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
- The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. Guise CP, et al. Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145130 - Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM, Ashoorzadeh A, Williams EM, Copp JN, Silva S, Bull MR, Abbattista MR, Anderson RF, Flanagan JU, Guise CP, Ackerley DF, Smaill JB, Patterson AV. Mowday AM, et al. Biochem Pharmacol. 2016 Sep 15;116:176-87. doi: 10.1016/j.bcp.2016.07.015. Epub 2016 Jul 22. Biochem Pharmacol. 2016. PMID: 27453434 - Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
Stornetta A, Deng KK, Danielli S, Liyanage HDS, Sturla SJ, Wilson WR, Gu Y. Stornetta A, et al. Biochem Pharmacol. 2018 Aug;154:64-74. doi: 10.1016/j.bcp.2018.04.004. Epub 2018 Apr 7. Biochem Pharmacol. 2018. PMID: 29630868 - Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC, Jin Y, Penning TM. Byrns MC, et al. J Steroid Biochem Mol Biol. 2011 May;125(1-2):95-104. doi: 10.1016/j.jsbmb.2010.11.004. Epub 2010 Nov 16. J Steroid Biochem Mol Biol. 2011. PMID: 21087665 Free PMC article. Review. - AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.
Li M, Zhang L, Yu J, Wang X, Cheng L, Ma Z, Chen X, Wang L, Goh BC. Li M, et al. Front Pharmacol. 2024 Mar 8;15:1378292. doi: 10.3389/fphar.2024.1378292. eCollection 2024. Front Pharmacol. 2024. PMID: 38523637 Free PMC article. Review.
Cited by
- AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.
Reddi D, Seaton BW, Woolston D, Aicher L, Monroe LD, Mao ZJ, Harrell JC, Radich JP, Advani A, Papadantonakis N, Yeung CCS. Reddi D, et al. Sci Rep. 2022 Apr 6;12(1):5809. doi: 10.1038/s41598-022-09697-6. Sci Rep. 2022. PMID: 35388063 Free PMC article. - The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, Soverini S. Bruno S, et al. Int J Mol Sci. 2021 Jun 25;22(13):6857. doi: 10.3390/ijms22136857. Int J Mol Sci. 2021. PMID: 34202238 Free PMC article. Review. - Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW, Wouters BG, Wilson WR. Hunter FW, et al. Br J Cancer. 2016 May 10;114(10):1071-7. doi: 10.1038/bjc.2016.79. Epub 2016 Apr 12. Br J Cancer. 2016. PMID: 27070712 Free PMC article. Review. - Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Konopleva M, et al. Haematologica. 2015 Jul;100(7):927-34. doi: 10.3324/haematol.2014.118455. Epub 2015 Feb 14. Haematologica. 2015. PMID: 25682597 Free PMC article. Clinical Trial. - Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Karunasinghe N, Symes E, Gamage A, Wang A, Murray P, Zhu S, Goudie M, Masters J, Ferguson LR. Karunasinghe N, et al. PLoS One. 2019 May 24;14(5):e0217373. doi: 10.1371/journal.pone.0217373. eCollection 2019. PLoS One. 2019. PMID: 31125365 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials